Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (3148)	6/2/1999 11:14:00 AM
From: Don Miller	Read Replies (2) \| Respond to of 10280

Basis SEPR PR, UBC deal is for ALL COUNTRIES except US and Japan, not Europe alone. See: quicken.com "Under the terms of the agreement, Sepracor has exclusively licensed to UCB all of Sepracor's issued patents and pending patent applications regarding levocetirizine in Europe and all other countries, except the United States and Japan. UCB will begin to pay Sepracor royalties upon first product sale, and royalties will escalate upon achievement of sales volume milestones." Neither UBC Reuters report stressed the extent of this agreement: quicken.com nor quicken.com Will UBC have more than a European marketing effort? Is UBC marketing Zyrtec out side or Europe?